Gordon, K., R. Warren, A. Gottlieb, A. Blauvelt, D. Thaçi, Y. Poulin, M. Boehnlein, F. Brock, C. Arendt, and K. Reich. “Durable Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks Over 128 Weeks in Patients With Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s81, doi:10.25251/skin.4.supp.81.